Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
10
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[THE INVESTOR] Samsung BioLogics issued 50 billion won (US$45.31 million) worth of private placement bonds, local media reported on Aug. 12.
Citing financial industry sources, the news reports stated that the company issued 1-year private placement bonds. This is the third time the company has issued bonds this year. In January and March, the company had issued bonds with a combined value of 120 billion won.
The company said that the bonds were issued to raise money to cover the cost of building its third plant. The company is the world’s third largest biologics contract manufacturer by capacity.
By Choi He-suk (cheesuk@heraldcorp.com)
Citing financial industry sources, the news reports stated that the company issued 1-year private placement bonds. This is the third time the company has issued bonds this year. In January and March, the company had issued bonds with a combined value of 120 billion won.
The company said that the bonds were issued to raise money to cover the cost of building its third plant. The company is the world’s third largest biologics contract manufacturer by capacity.
By Choi He-suk (cheesuk@heraldcorp.com)
